[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"fertility-issues\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:fertility-issues":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,16,0,[8,44,73,98,134,155,190,215,242,272,294,322,345,373,396,419],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100463576","phase-2-weight-management-plus-lng-iusmegestrol-acetate-in-endometrial-atypical-hyperplasia-100463576",false,"NCT05316493","Weight Management Plus LNG-IUS\u002FMegestrol Acetate in Endometrial Atypical Hyperplasia","Weight Management Plus Levonorgestrel Intrauterine System or Megestrol Acetate in Endometrial Atypical Hyperplasia: Multiple Single-arm, Prospective and Open-label Clinical Study","Inclusion Criteria:\n\n1.18 years≤age≤45years 2.BMI (body mass index) ≥24kg\u002Fm2 3.Consent informed and signed 4.Pathologically confirmed as endometrial atypical hyperplasia. Patients with endometrial specimens obtained by endometrial biopsy, diagnostic curettage or hysteroscopy and diagnosed histologically as endometrial atypical hyperplasia. If specimens are from other hospitals, they must be counseled or reconfirmed by the Department of Pathology of the Obstetrics and Gynecology Hospital of Fudan University.\n\n5.Have a strong desire to reproduce and ask for fertility preservation or those who insist on keeping the uterus despite no reproductive requirements.\n\n6.Have good compliance and follow-up conditions, and patients are willing to follow up in Obstetrics and Gynecology Hospital of Fudan University in time.\n\nExclusion Criteria:\n\n1. Combined with severe medical disease or liver or kidney dysfunction: alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level elevates to 3 times or more of the upper limit of normal, kidney dysfunction (creatinine clearance \\\u003C 30 mL\u002Fmin)\n2. Patients are diagnosed with other malignant tumors of the reproductive system; patients with breast cancer or other hormone-dependent tumors that cannot be used with progesterone.\n3. Those who have received high doses of high potency progestin or oral contraceptives within the last 3 months (or those on maintenance medication).\n4. Those who require hysterectomy or other methods other than conservative treatment.\n5. Known or suspected pregnancy.\n6. Those who has contraindications to use progestin.\n7. Deep vein thrombosis, stroke, myocardial infarction.\n8. Severe joint lesions that prevent walking or movement.\n9. untreated or recurrent pelvic inflammatory disease (PID)\n10. an untreated or uncontrolled pelvic infection (vaginal, cervical, uterine);\n11. Cervical dysplasia\n12. Congenital or acquired uterine abnormalities, including uterine fibroid tumors or conditions that affect the shape of the uterus\n13. allergic to the LNG-IUS components\n14. uterine cavity is too large (average uterine diameter is over 7 cm) or have a history of LNG-IUS falling out.\n\nNotes: the last 6 criteria are only applied for patients with LNG-IUS.","FEMALE","18 Years","45 Years",{"count":20,"type":21},172,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE2","PHASE3","To investigate the efficacy of weight management plus levonorgestrel intrauterine system (LNG-IUS) or megestrol acetate (MA) in obese patients with endometrial atypical hyperplasia (EAH) asking for conservative therapy.",[28,29,30],"Atypical Endometrial Hyperplasia","Fertility Issues","Overweight and Obesity","RECRUITING","2026-06-03",{"date":34,"type":35},"2026-06-04","ACTUAL",{"date":37,"type":35},"2022-06-13",{"date":39,"type":21},"2027-02-28",{"name":41,"class":42},"Xiaojun Chen","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":57,"conditions":58,"keywords":61,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100596827","a-multicenter-prospective-randomized-controlled-clinical-trial-comparing-constant-5-versus-sequential-5-2-oxygen-concentration-embryo-culture-protocols-in-assisted-reproductive-technology-100596827","NCT07050537","A Multicenter Prospective Randomized Controlled Clinical Trial Comparing Constant (5%) Versus Sequential (5%-2%) Oxygen Concentration Embryo Culture Protocols in Assisted Reproductive Technology","A Multicenter Prospective Randomized Controlled Clinical Trial Comparing Constant (5%) Versus Sequential (5%-2%) Oxygen Concentration Embryo Culture Protocols in Assisted Reproductive Technology: Evaluating Term Live Birth and Offspring Health Outcomes","Inclusion Criteria:\n\n1. Female: age ≥20 and ≤40 years, male: age ≥20 and ≤50 years;\n2. Proposed 1st or 2nd cycle of IVF or ICSI fertilization;\n3. ≥ 4 transferable embryos at oocyte stage.\n\nExclusion Criteria:\n\n1. Diagnosis of abnormal uterine cavity morphology (confirmed by 3D ultrasound or hysteroscopy), including uterine malformations (mediastinal uterus, unicornuate uterus, bicornuate uterus), submucosal uterine fibroids, or uterine adhesions;\n2. Patients who are proposed to undergo IVM;\n3. Patients who are proposed to undergo PGD\u002F PGS;\n4. Patients with untreated severe hydrosalpinx (confirmed by ultrasound or HSG);\n5. Patients with a history of recurrent miscarriage (2 or more previous pregnancy losses, excluding biochemical pregnancies);\n6. Patients who plan to freeze whole embryos and are unable to complete a single embryo transfer within six months;\n7. Patients with contraindications to assisted reproductive technology and pregnancy, or suffering from diseases that have a definite effect on pregnancy: including uncontrolled hypertension, heart disease with definite symptoms, uncontrolled diabetes, undefined diagnosis of liver or kidney disease or liver or kidney insufficiency, severe anemia, history of previous venous thrombosis, pulmonary embolism or cerebrovascular events, history of malignant tumors, suspected malignant tumors, and undiagnosed abnormal uterine bleeding.","20 Years","40 Years",{"count":54,"type":21},980,[56],"NA","To evaluate whether there were significant differences in the effects of constant (5%) versus sequential (5%-2%) oxygen concentration protocols in embryo culture on term live birth rates.\n\nThis study will be conducted in five centers including the Clinical Center of Reproductive Medicine, First Affiliated Hospital of Nanjing Medical Universit. 980 women who wish to undergo blastocyst transplantation will be included in the study.\n\nThe study data will be analyzed statistically.",[29,59,60],"Blastocyst IVF","Embryo Culture",[59,62],"Fertility","2026-05-29",{"date":65,"type":35},"2026-06-01",{"date":67,"type":35},"2025-03-01",{"date":69,"type":21},"2027-08-31",{"name":71,"class":42},"The First Affiliated Hospital with Nanjing Medical University",6,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":80,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":22,"phases":84,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":43},"100599377","frame-support-study-100599377","NCT07083700","Frame Support Study","The Impact of the Frame™ Platform on Infertility Patient Retention and Emotional Health: A Randomized Controlled Pilot Study","Inclusion Criteria:\n\n* Participants have completed a new patient consult at one of the participating fertility clinics\n* Participants must be able to read, write and speak English\n* Participants must have access to a smart phone and internet connection\n\nExclusion Criteria:\n\n* Patients who are currently using a fertility coach (in-person, remote, or online)\n* Patients planning egg freezing only\n* Patients who have received treatment at another fertility center\n* Patients planning egg donation\n* Patients currently participating in another clinical trial or study involving an intervention.","22 Years","44 Years",{"count":83,"type":21},400,[56],"This is a randomized, controlled pilot study evaluating an intervention of non-significant risk. Potential subjects will be women who have completed an initial new patient consultation at one of the participating fertility clinics. Approximately 400 subjects will be enrolled from multiple fertility clinics.",[29,87],"Emotional Stress","2026-04-13",{"date":90,"type":35},"2026-04-15",{"date":92,"type":35},"2025-06-23",{"date":94,"type":21},"2027-06",{"name":96,"class":97},"Inception Fertility Research Institute, LLC","INDUSTRY",{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":106,"sex":107,"minAge":108,"maxAge":109,"enrollmentInfo":110,"targetDuration":4,"studyType":112,"phases":4,"briefSummary":113,"conditions":114,"keywords":116,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":43},"100538622","towards-optimal-fertility-fathering-and-fatherhood-study-100538622","NCT06293235","Towards Optimal Fertility, Fathering and Fatherhood studY","Investigating Male Factors and Their Relationships With Reproductive Health Outcomes in Singapore: Towards Optimal Fertility, Fathering and Fatherhood studY","TOFFFY","Inclusion Criteria:\n\nSubfertile couples:\n\n* men aged ≥21-49 years\n* men with a female partner aged 21-39 years\n* couples who are not able to conceive for at least 12 months\n* couples who are Singapore citizen or permanent resident\n\nFertile couples:\n\n* men aged 21-49 years\n* men with a female partner aged 21-39 years\n* men with proven fertility defined as those female partners who are currently pregnant and with viable intrauterine pregnancy at gestational weeks of less or equal to 16 at the time of the study\n* couples with attempted time to conceive within 12 months to achieve this pregnancy or with unplanned pregnancy\n* couples who are Singapore citizen or permanent resident\n\nExclusion Criteria:\n\nSubfertile couples:\n\n* male infertility of a known aetiology including azoospermia, retrograde ejaculation, genetic disorders, cancer treatment, or testes trauma\n* female infertility diagnosis as confirmed by diagnostic imaging or having severe endometriosis\n* female partners with irregular menstrual cycle \\>35 days\n* couples with known chromosomal abnormalities\n\nFertile couples:\n\n* couples who achieve pregnancy after oocyte or spermatozoa donation\n* couples with known chromosomal abnormalities\n* female partners with known uterine abnormalities",true,"ALL","21 Years","49 Years",{"count":111,"type":21},960,"OBSERVATIONAL","This case-control study involving fertile and subfertile couples aims to identify male factors related to pregnancy likelihood, create a fertility index measure combining male and female factors to predict pregnancy likelihood, and examine how male factors relate to the semen physical and biological characteristics.",[115,29],"Reproductive Issues",[117,118,119,120,121,122,123],"Male","Risk factor","Lifestyle","Semen analysis","Epigenetic","Oxidative stress","DNA fragmentation","2026-03-17",{"date":126,"type":35},"2026-03-20",{"date":128,"type":35},"2024-06-21",{"date":130,"type":21},"2027-09",{"name":132,"class":133},"KK Women's and Children's Hospital","OTHER_GOV",{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":138,"acronym":4,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":107,"minAge":4,"maxAge":140,"enrollmentInfo":141,"targetDuration":4,"studyType":112,"phases":4,"briefSummary":143,"conditions":144,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":43},"100519443","outcome-evaluation-after-fertility-preservation-100519443","NCT06043609","Outcome Evaluation After Fertility Preservation","Inclusion Criteria:\n\n* Patients aged from 0-50 years old\n* Patients with any illness or who will undergo any type of treatment that may cause irreversible damage to their fertility, such as extensive abdominal surgery, high toxicity medication and treatments;\n* Patients seek for fertility preservation services\n\nExclusion Criteria:\n\n-Patients unable to provide consent\u002Fassent (i.e. significant psychiatric problems\u002Fcognitive delay)","60 Years",{"count":142,"type":21},100,"It is important to evaluate outcomes after different fertility preservation strategies. Therefore, this study aims to assess the outcomes after different fertility preservation strategies and identify any factors that may affect their reproductive outcome.",[145,29],"Cancer","2026-01-06",{"date":148,"type":35},"2026-01-08",{"date":150,"type":35},"2023-09-21",{"date":152,"type":21},"2035-10-01",{"name":154,"class":42},"Chinese University of Hong Kong",{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":161,"eligibilityCriteria":162,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":163,"targetDuration":4,"studyType":22,"phases":165,"briefSummary":167,"conditions":168,"keywords":172,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":43},"100445448","phase-4-luteal-phase-support-in-iui-moh-treatment-luteal-phase-support-in-iui-moh-treatment-100445448","NCT05080569","Luteal Phase Support in IUI MOH Treatment Luteal Phase Support in IUI MOH Treatment","LUMO Study: Luteal Phase Support in IUI MOH Treatment Luteal Phase Support in IUI MOH","LUMO","Inclusion Criteria:\n\n* Couples starting IUI with Mild Ovarian HyperStimulation (MOH), with the intend to receive this treatment for at least six months.\n* Diagnosis of unexplained (primary or secondary) infertility\n* Hunault \\\u003C30% (or \\>30%, after an expectant management period of at least 6 additional months).\n* Females aged \\>18 years with regular menstrual cycle.\n* Total mobile sperm count (VCM) \\>10 million.\n\nExclusion cirteria:\n\n* Cycle irregularities\n* Male factor infertility",{"count":164,"type":21},1008,[166],"PHASE4","The LUMO study is a multicenter, randomized controlled trial that evaluates the effectivity of luteal phase support in MOH\u002FIUI treatment.",[169,29,170,171],"Pregnancy Related","Luteal Phase Defect","Infertility Unexplained",[173,174,175,176,177,178,179,180],"progesterone","Cost-effective","Intrauterine insemination","live birth","luteal support","ongoing pregnancy","ovulation induction","unexplained infertility","2025-12-23",{"date":183,"type":35},"2025-12-31",{"date":185,"type":35},"2023-03-01",{"date":187,"type":21},"2027-07",{"name":189,"class":42},"UMC Utrecht",{"id":191,"slug":192,"hasResults":11,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":196,"eligibilityCriteria":197,"healthyVolunteers":11,"sex":198,"minAge":4,"maxAge":4,"enrollmentInfo":199,"targetDuration":4,"studyType":22,"phases":201,"briefSummary":202,"conditions":203,"keywords":204,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":213,"locationsCount":43},"100545867","testicular-tissue-cryopreservation-ttc-100545867","NCT06387498","Testicular Tissue Cryopreservation (TTC)","Testicular Tissue Cryopreservation for Fertility Preservation in Patients Facing Infertility-causing Diseases or Treatment Regimens.","TTC","Inclusion Criteria:\n\n1. Male at any age.\n2. Scheduled to undergo surgery, chemotherapy, drug treatment and\u002For radiation for the treatment or prevention of a medical condition or malignancy with risk of causing permanent and complete loss of subsequent testicular function. Be in significant risk of infertility as defined by:\n\n   * Cyclophosphamide equivalent dose (CED) ≥4 g\u002Fm2\n   * Total body irradiation (TBI)\n   * Testicular radiation \\>2.5 Gy\n   * Cisplatin 500 mg\u002Fm2\n   * Bone Marrow Transplant (BMT)\n3. Or have a medical condition or malignancy that requires removal of all or part of one or both testicles.\n4. Or have newly diagnosed or recurrent disease. Those who were not enrolled at the time of initial diagnosis (i.e., patients with recurrent disease) are eligible if they have not previously received therapy that is viewed as likely to result in complete and permanent loss of testicular function.\n5. Have two testicles if undergoing elective removal of a testicle for fertility preservation only. Note: removal of both testicles will limit fertility preservation options.\n6. Sign an approved informed consent and authorization permitting the release of personal health information. The patient and\u002For the patient's legally authorized guardian must acknowledge in writing that consent for specimen collection has been obtained, in accordance with institutional policies approved by the U.S. Department of Health and Human Services.\n7. Consent for serum tests for infectious diseases \\[including Hepatitis B Surface Antigen, Hepatitis C Virus (HCV) Antibody, and Human Immunodeficiency Virus (HIV) antigen\u002Fantibody screen to be performed at the time of testicular tissue harvesting.\n8. Undergo a full history and physical examination and obtain standard pre-operative clearance (based on the most recent American College of Cardiology\u002FAmerican Heart Association (ACC\u002FAHA) Guideline for Perioperative Cardiovascular Evaluation for Noncardiac Surgery) as determined by their primary surgeon.\n\nExclusion Criteria\n\nPatients will be ineligible for participation in this study if they are:\n\n1. Diagnosed with psychological, psychiatric, or other conditions which prevent giving fully informed consent.\n2. Diagnosed with an underlying medical condition that significantly increases their risk of complications from anesthesia and surgery.","MALE",{"count":200,"type":21},60,[56],"The \"Testicular Tissue Cryopreservation\" study is open to a subset of patients facing disease or treatment regimens that could lead to infertility (gonadotoxic therapies). For some of these patients, experimental testicular tissue cryopreservation is the only fertility preservation option available. The overall objective of this study is to determine the feasibility and acceptability of testicular tissue cryopreservation in male patients of all ages who have a condition or will undergo a treatment that can cause infertility.",[29],[205],"Fertility preservation","2025-09-12",{"date":208,"type":35},"2025-09-16",{"date":210,"type":35},"2020-09-28",{"date":212,"type":21},"2027-12-30",{"name":214,"class":42},"University of Colorado, Denver",{"id":216,"slug":217,"hasResults":11,"nctId":218,"briefTitle":219,"officialTitle":219,"acronym":4,"eligibilityCriteria":220,"healthyVolunteers":11,"sex":16,"minAge":221,"maxAge":222,"enrollmentInfo":223,"targetDuration":4,"studyType":22,"phases":225,"briefSummary":226,"conditions":227,"keywords":229,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":233,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":239,"locationsCount":241},"100567119","intervening-on-womens-health-for-rural-young-cancer-survivors-100567119","NCT06664034","Intervening on Women's Health for Rural Young Cancer Survivors","Inclusion Criteria:\n\n* Cancer (Stages 0-IV) diagnosis\n* Primary language English or Spanish\n* Receiving oncology care at rural oncology clinical participating site\n* Living in Imperial County, California\n\nExclusion Criteria:\n\n\\- Women who are pregnant at recruitment","15 Years","50 Years",{"count":224,"type":21},64,[56],"The purpose of this pilot study is to evaluate the feasibility of a multi-component intervention to improve young female cancer survivors' engagement in goal-concordant reproductive health care. The investigators hypothesize that implementation of the intervention will result in increased young cancer survivors' engagement in goal-concordant reproductive health care.",[145,29,228],"Contraception",[230,231],"Reproductive health","Oncofertility","2025-08-27",{"date":234,"type":35},"2025-09-04",{"date":236,"type":35},"2024-12-01",{"date":238,"type":21},"2026-05-31",{"name":240,"class":42},"University of California, San Diego",4,{"id":243,"slug":244,"hasResults":11,"nctId":245,"briefTitle":246,"officialTitle":246,"acronym":4,"eligibilityCriteria":247,"healthyVolunteers":11,"sex":16,"minAge":248,"maxAge":81,"enrollmentInfo":249,"targetDuration":4,"studyType":112,"phases":4,"briefSummary":251,"conditions":252,"keywords":256,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":265,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":271,"locationsCount":43},"100505204","clinical-application-of-serum-anti-mllerian-hormone-amh-measurements-100505204","NCT05858307","Clinical Application of Serum Anti-Müllerian Hormone (AMH) Measurements","Inclusion Criteria:\n\n* Women attending the Paediatric and Adolescent Gynaecological Clinic and Gynaecological Endocrine Clinic of in the Department of Obstetrics and Gynaecology at the Prince of Wales Hospital for the management of PCOS and POI\n* Women attending the Assisted Reproductive Technology (ART) Unit of The Chinese University of Hong Kong for ART treatment\n\nExclusion Criteria:\n\n* Women with age \\\u003C10 or ≥45\n* Current or past diseases affecting gonadotropin, sex steroid secretion, clearance and excretion","10 Years",{"count":250,"type":21},300,"This study aims to assess the association of Anti-Müllerian hormone (AMH) with polycystic ovarian syndrome, premature ovarian insufficiency and fertility. The main objectives include the following:\n\n1. To study the level of serum AMH in women with PCOS and to evaluate the utility of serum AMH in the diagnosis of PCOS.\n2. To evaluate the level of serum AMH in women with POI and to evaluate the utility of serum AMH in the management of POI.\n3. To evaluate the associations of basal AMH level with FSH level and AFC respectively for women undergoing ART treatment.\n4. To determine the optimal regimen of gonadotropin for ovarian stimulation for women undergoing ART treatment.\n5. To evaluate the predictive value of serum AMH in reproductive outcomes including oocyte quality, embryo quality, pregnancy loss, clinical pregnancy and live birth rate in women undergoing ART treatment.",[253,254,255,29],"Anti-Müllerian Hormone","Polycystic Ovarian Syndrome","Premature Ovarian Insufficiency",[257,254,255,258,259,260,261,262,263],"Anti-Müllerian hormone","Assisted Reproductive Technology treatment","Predictive value","Reproductive outcomes","AMH","PCOS","POI","2025-03-26",{"date":266,"type":35},"2025-03-27",{"date":268,"type":35},"2022-06-22",{"date":270,"type":21},"2026-12-31",{"name":154,"class":42},{"id":273,"slug":274,"hasResults":11,"nctId":275,"briefTitle":276,"officialTitle":277,"acronym":4,"eligibilityCriteria":278,"healthyVolunteers":106,"sex":198,"minAge":17,"maxAge":222,"enrollmentInfo":279,"targetDuration":4,"studyType":112,"phases":4,"briefSummary":281,"conditions":282,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":285,"lastUpdatePostDateStruct":286,"startDateStruct":288,"completionDateStruct":290,"leadSponsor":292,"locationsCount":43},"100556890","the-effect-of-tucking-on-semen-quality-of-adult-trans-women-100556890","NCT06530992","The Effect of Tucking on Semen Quality of Adult Trans Women","The Effect of Tucking on Semen Quality of Adult Trans Women Compared to Semen Quality of Trans Women Who do Not Tuck - a Case Control Study","Inclusion Criteria:\n\n* Female transgender patients between the ages of 18 to 50 years of age who are seen at the University Clinic for Gyn. Endocrinology and Reproductive Medicine of the Medical University of Innsbruck. Patients must have met the eligibility and readiness criteria for gender-affirming hormone therapy\n\nExclusion Criteria:\n\n* Ongoing GAHT gender affirming genital surgery Hypogonadism Diabetes mellitus Cystic Fibrosis Varicocele Cryptorchism Post-sterilization Incapacity to consent",{"count":280,"type":21},40,"Because gender-affirming hormone therapy (GAHT) can lead to fertility impairment, current guidelines and treatment recommendations require that patients be informed about the possibility of fertility preservation prior to initiating GAHT. A recent review by our working group analyzed the current data on fertility and fertility preservation in transgender and gender diverse people. Several studies were identified that evaluated semen quality before and during GAHT in trans women compared to reproductive men. All studies showed a significant reduction in semen quality even before GAHT. In addition, one study found evidence that constant wearing of tight underwear and tucking was associated with a reduction in motile sperm concentration to \\\u003C5 mill\u002Fml. Tucking is a method of avoiding crotch bulge through the penis and testicles by placing the penis backwards between the legs and optionally pushing the testicles into the groin canals. These positions are fixed with tight-fitting underwear or gaffs. Whether tucking or the wearing of tight underwear is the determining factor for impaired semen quality even before the start of GAHT and whether there is reversibility remains unclear and will be investigated in the present study.\n\nThe study is designed as a prospective case-control study with a total sample size of n = 40 trans women. All patients with gender incongruence presenting to the University Clinic for Gynecology, Endocrinology and Reproduction Innsbruck before starting GAHT are eligible to participate. Trans women (n = 20) who practice tucking or wear tight underwear will be included and trans women (n = 20) who do not practice tucking will be included as a control group. At Time 1, after 2-7 days of abstinence, all participants will provide a semen sample for a spermiogram, a venous blood sample will be taken, and quality of life will be assessed using a questionnaire. The frequency and duration of tucking or wearing tight underwear, ejaculation frequency, demographic data such as BMI, nicotine use, alcohol and drug use, medication use, underlying medical conditions, previous surgeries, etc. are also recorded.\n\nParticipants in the study group are then asked to abstain tucking for at least 73 days. After 2-7 days of sperm abstinence, another semen sample is taken at time 2, a venous blood sample is taken, and quality of life is assessed. At this point, depending on the participant's wishes, there is the option of sperm cryopreservation for fertility preservation prior to starting GAHT.\n\nSpermiograms are performed under standardized conditions according to current WHO guidelines.",[283,284,29],"Transgender","Gender Incongruence","2024-07-29",{"date":287,"type":35},"2024-07-31",{"date":289,"type":35},"2024-07-17",{"date":291,"type":21},"2029-12",{"name":293,"class":42},"Medical University Innsbruck",{"id":295,"slug":296,"hasResults":11,"nctId":297,"briefTitle":298,"officialTitle":299,"acronym":4,"eligibilityCriteria":300,"healthyVolunteers":106,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":301,"targetDuration":4,"studyType":22,"phases":303,"briefSummary":304,"conditions":305,"keywords":308,"overallStatus":312,"whyStopped":4,"lastUpdateSubmitDate":313,"lastUpdatePostDateStruct":314,"startDateStruct":315,"completionDateStruct":317,"leadSponsor":319,"locationsCount":43},"100546549","phase-4-comparison-of-progestin-primed-ovarian-stimulation-ppos-vsgnrh-antagonist-methods-on-ivf-outcomes-100546549","NCT06396390","Comparison of Progestin Primed Ovarian Stimulation (PPOS) vs.GnRH Antagonist Methods on IVF Outcomes","The Comparative Results of Progestin Primed Ovarian Stimulation (PPOS) and GnRH Antagonist Ovarian Stimulation Methods on IVF Outcomes","Inclusion Criteria:\n\n* BMI \\> 18 kg\u002Fm2 ve \\\u003C35 kg\u002Fm2\n* Couples that accept being included in the study\n* Couple accepting thawed embryo transfer\n\nExclusion Criteria:\n\n* Known chromosomal abnormality in either member of the couple\n* Couples with unexplained infertility\n* BMI \\> 30 kg\u002Fm2\n* Mullerian malformations\n* Undergoing oocyte cryopreservation for medical reasons (such as malignancies)\n* Couple insists on fresh embryo transfer",{"count":302,"type":21},152,[166],"The goal of this randomized clinical trial is to compare the effects of two different ovarian stimulation methods: Progestin Primed Ovarian Stimulation (PPOS) vs. GnRH Antagonist in embryologic outcomes of IVF Patients.",[306,29,307],"IVF","Infertility",[309,310,307,311],"GnRH Antagonist","Progestin Primed Ovarian Stimulation","Ovarian Stimulation","NOT_YET_RECRUITING","2024-07-15",{"date":289,"type":35},{"date":316,"type":21},"2024-08-01",{"date":318,"type":21},"2026-08-01",{"name":320,"class":321},"Nesta Clinic","NETWORK",{"id":323,"slug":324,"hasResults":11,"nctId":325,"briefTitle":326,"officialTitle":326,"acronym":327,"eligibilityCriteria":328,"healthyVolunteers":106,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":329,"targetDuration":4,"studyType":112,"phases":4,"briefSummary":330,"conditions":331,"keywords":332,"overallStatus":312,"whyStopped":4,"lastUpdateSubmitDate":336,"lastUpdatePostDateStruct":337,"startDateStruct":339,"completionDateStruct":341,"leadSponsor":343,"locationsCount":43},"100547607","correlation-of-urinary-and-serum-hormone-levels-in-natural-cycle-frozen-embryo-transfer-cycles-100547607","NCT06410170","Correlation of Urinary and Serum Hormone Levels in Natural Cycle Frozen Embryo Transfer Cycles","MIRA","Inclusion Criteria:\n\n* All patients scheduled for a natural cycle frozen embryo transfer\n* Agree to participate in the research study\n\nExclusion Criteria:\n\n* There are no exclusions",{"count":142,"type":21},"To evaluate whether the measurement of urinary estrone glucuronide and luteinizing hormone (LH) concentrations with an at-home device is correlated with serum hormone levels within a natural cycle frozen embryo transfer protocol.\n\nThe hypothesis is that home urinary monitoring can reliably detect the LH surge and serve as a trigger for timing the FET. Results of this study may ultimately lead to change in clinical practice by reducing the number of clinic visits for serum monitoring, offering a more convenient, time and cost saving method of detection of LH surge. If the proposed protocol were feasible and widely accepted by patients, this would prompt the wide adoption of a less invasive but equally as effective FET protocol.",[29],[333,334,335],"Mira device","Fertility tracking","At home use","2024-06-06",{"date":338,"type":35},"2024-06-10",{"date":340,"type":21},"2024-06",{"date":342,"type":21},"2025-12",{"name":344,"class":42},"Ottawa Fertility Centre",{"id":346,"slug":347,"hasResults":11,"nctId":348,"briefTitle":349,"officialTitle":350,"acronym":351,"eligibilityCriteria":352,"healthyVolunteers":11,"sex":107,"minAge":353,"maxAge":222,"enrollmentInfo":354,"targetDuration":248,"studyType":112,"phases":4,"briefSummary":356,"conditions":357,"keywords":362,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":364,"lastUpdatePostDateStruct":365,"startDateStruct":367,"completionDateStruct":369,"leadSponsor":371,"locationsCount":43},"100507258","impact-of-gonadotoxic-therapies-on-fertility-100507258","NCT05885048","Impact of Gonadotoxic Therapies on Fertility","FertiTOX - Platform for Fertility Related Gonadotoxicity of Cancer Therapies","FertiTOX","Inclusion Criteria:\n\n* Patients with cancer or with benign reasons undergoing chemotherapy and\u002For radiotherapy of the pelvis (females) and the testicles (males) and\u002For immune therapy;\n* Willing to participate;\n* Austria: 14-50 years old (adolescents and adults), Germany: 18-50 years old, Switzerland: 14-50 years old (adolescents and adults);\n* Serum hormone analysis before gonadotoxic therapy (females) or serum hormone analysis and sperm analysis before gonadotoxic therapy (males).\n\nExclusion Criteria:\n\n* Missing consent;\n* Language barrier.","14 Years",{"count":355,"type":21},7000,"The goal of this observational study is to learn how gonadotoxic treatments (chemotherapies, radiotherapies or immunotherapies) affect the fertility status of participants with cancer.\n\nThe main questions it aims to answer are:\n\n* in females, if cancer therapies reduce the Anti-Müllerian hormone (AMH) concentration (ovarian reserve);\n* in males, if cancer therapies reduce sperm concentration (sperm quality).",[145,29,358,359,360,361],"Fertility Preservation","Toxicity Due to Chemotherapy","Toxicity Due to Radiotherapy","Effects of Immunotherapy",[363],"Gonadotoxicity","2024-05-31",{"date":366,"type":35},"2024-06-03",{"date":368,"type":35},"2023-12-01",{"date":370,"type":21},"2038-12-31",{"name":372,"class":42},"Michael von Wolff",{"id":374,"slug":375,"hasResults":11,"nctId":376,"briefTitle":377,"officialTitle":378,"acronym":4,"eligibilityCriteria":379,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":52,"enrollmentInfo":380,"targetDuration":382,"studyType":112,"phases":4,"briefSummary":383,"conditions":384,"keywords":385,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":388,"lastUpdatePostDateStruct":389,"startDateStruct":391,"completionDateStruct":393,"leadSponsor":395,"locationsCount":43},"100543792","fertility-preservation-and-pregnancy-and-offspring-health-outcomes-in-female-cancer-100543792","NCT06360471","Fertility Preservation and Pregnancy and Offspring Health Outcomes in Female Cancer","Fertility Preservation and Pregnancy and Offspring Health Outcomes in Female Cancer Patients: A Multicenter, Prospective, Cohort Study","Inclusion Criteria:\n\n1. Tumor confirmed (main focus: breast cancer, hematological disease\u002Flymphoma, gynecological tumor (ovarian cancer), boundary tumors, nasopharyngeal cancer, colorectal cancer, and other tumors that require anti-tumor treatment;\n2. Having a desire for future fertility(including women who have already given birth);\n3. Age: 20-40 years old (patients planning to freeze their eggs are ≤35 years old, and those planning to freeze their embryos are ≤40 years old);\n4. Consent.\n\nExclusion Criteria:\n\n1. Patients with congenital or acquired uterine abnormalities, severe intrauterine adhesions, and other diseases that have a clear impact on pregnancy;\n2. Those with assisted reproductive technology and pregnancy contraindications;\n3. Tumors that are not suitable for pregnancy after multidisciplinary discussions on tumor fertility;\n4. Clinical diagnosis of POI (premature ovarian insufficiency).",{"count":381,"type":21},2800,"5 Years","To explore whether there is a significant difference in the cumulative live birth rate and maternal and child health outcomes between cancer patients who undergo or do not undergo fertility preservation before receiving anti-tumor treatment and non-cancer patients who undergo assisted reproductive technology treatment\u002Fnatural pregnancy.\n\nThis study will be conducted in the Clinical Center of Reproductive Medicine, First Affiliated Hospital of Nanjing Medical University. 2800 women diagnosed with malignant cancers who has desire to reproduce will be enrolled in this study.\n\nStatistical analysis of the data will be performed.",[29,145],[386,387],"fertility preservation","cancer","2024-04-15",{"date":390,"type":35},"2024-04-16",{"date":392,"type":35},"2023-10-01",{"date":394,"type":21},"2032-10-01",{"name":71,"class":42},{"id":397,"slug":398,"hasResults":11,"nctId":399,"briefTitle":400,"officialTitle":401,"acronym":4,"eligibilityCriteria":402,"healthyVolunteers":11,"sex":198,"minAge":17,"maxAge":222,"enrollmentInfo":403,"targetDuration":4,"studyType":112,"phases":4,"briefSummary":405,"conditions":406,"keywords":407,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":410,"lastUpdatePostDateStruct":411,"startDateStruct":413,"completionDateStruct":415,"leadSponsor":417,"locationsCount":43},"100531034","assessing-the-fertility-status-of-men-with-spinal-muscular-atrophy-sma-100531034","NCT06194539","Assessing the Fertility Status of Men With Spinal Muscular Atrophy (SMA)","The Assessment of Fertility in Men With Spinal Muscular Atrophy (SMA)","Inclusion Criteria:\n\n* Signed Informed Consent Form (or assent)\n* Male and age greater than 18 years and less than 50 years of age with a confirmed diagnosis of SMA at the time of signing the Informed Consent Form (or assent)\n* Currently not on a disease-modifying agent or therapy for SMA\n* Adequately recovered from any acute illness at the time of screening, and considered clinically well enough to participate in the study.\n\nExclusion Criteria:\n\nMen with a prior history of chemotherapy, radiation therapy, prostate or testicular cancer, undescended testicles and use of anabolic steroids or testosterone usage will be excluded",{"count":404,"type":21},75,"This study will aim to assess the fertility status of men with Spinal Muscular Atrophy (SMA) not on disease-modifying therapies.\n\nParticipants will:\n\n1. Complete online questionnaires that will assess SMA diagnosis and disease burden, medical and surgical history, medication usage, and fertility status and perspectives.\n2. Over the 3-month initial study baseline period participants will provide two separate ejaculates for semen analysis and a single determination of sperm quality using DNA fragmentation testing using home collection and subsequent shipment to a central laboratory.\n3. Over the initial study baseline period of 3 months study participants will obtain a blood test to determine male reproductive hormone levels.\n\nDuring the 24-month study duration, participants will be requested to undergo a yearly semen analysis and complete online relevant questionnaires.",[29],[408,409],"Men","Spinal Muscular Atrophy","2024-01-04",{"date":412,"type":35},"2024-01-08",{"date":414,"type":21},"2024-02",{"date":416,"type":21},"2026-07",{"name":418,"class":42},"Bar-Chama, Natan, M.D.",{"id":420,"slug":421,"hasResults":11,"nctId":422,"briefTitle":423,"officialTitle":424,"acronym":425,"eligibilityCriteria":426,"healthyVolunteers":11,"sex":107,"minAge":17,"maxAge":427,"enrollmentInfo":428,"targetDuration":248,"studyType":112,"phases":4,"briefSummary":430,"conditions":431,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":436,"lastUpdatePostDateStruct":437,"startDateStruct":439,"completionDateStruct":441,"leadSponsor":443,"locationsCount":43},"100414888","the-prospective-observational-compraya-cohort-study-100414888","NCT04682470","The Prospective Observational COMPRAYA Cohort Study","COMPRehensive Assessment of Prevalence, Risk Factors and Mechanisms of Impaired Medical and Psychosocial Health Outcomes Among Adolescents and Young Adults With Cancer: the Prospective Observational COMPRAYA Cohort Study","COMPRAYA","Inclusion Criteria:\n\n* Pathological confirmed cancer diagnosis;\n* Age 18 - 39 years at time of first cancer diagnosis;\n* Able to understand the informed consent form;\n* Provide written informed consent.\n\nExclusion Criteria:\n\n* Mentally incompetent patients based on the opinion of treating physician .\n* Inability to understand the Dutch language\n* Life expectancy less than 6 months based on the opinion of treating physician .","39 Years",{"count":429,"type":21},4000,"Rationale: Childhood cancer survivorship attracts attention globally, because successes in treatment have led to increasing number of survivors who reach adulthood, in which survivorship issues affecting health-related quality of life (HRQoL) become prominent. Most paediatric patients are treated intensively with irradiation and\u002For chemotherapy, which put them at risk for early and\u002For late adverse medical and psychosocial events. In contrast, much less is known about adolescent and young adult (AYA) cancer patients, diagnosed between 18-39 years, who, with an 80% chance to survive, also have a long life ahead. AYA cancer patients, much more than children, suffer from delay in diagnosis, lack of centralization of care, ageadjusted expertise, and AYA follow-up care. AYAs typically present with a rare tumour: either with a paediatric malignancy (e.g. acute lymphoblastic leukaemia, paediatric brain tumours), a more typical tumour of AYA age (e.g. Hodgkin's disease, germ cell cancer, melanoma, thyroid cancer) or with an adult tumour at unusual young age (e.g. gastrointestinal, lung, breast carcinomas). Next to these differences in epidemiology, the tumour biology, developmental challenges (e.g. forming relationships, becoming financially independent, having children) and treatment regimens differ between AYAs and children, and therefore findings derived from childhood cancer survivors cannot be extrapolated to AYAs. Furthermore, novel treatments with targeted agents or immunotherapy are more likely to be administrated to AYAs compared to children. Finally, a rare group of incurable AYA cancer patients will survive for many years, for whom health outcome and supportive care intervention data are lacking.\n\nGlobally, so far, the identification of AYA cancer patient subgroups that might be more susceptible to poor health outcomes has not been systematically addressed. The role of sociodemographic and treatment-associated risks, external exposures (e.g. lifestyle) and host factors (e.g. genetic, biological, physiological); or combinations of influences for impaired (agespecific) health outcomes, remains largely unknown. Understanding who is at risk and why will support the development of evidence-based AYA prevention, treatment and supportive care programs and guidelines, in co-creation with AYA cancer patients.\n\nObjective: To examine the prevalence, risk factors and mechanisms of impaired health outcomes (short- and long-term medical and psychosocial effects and late effects) over time among a population-based sample of AYA cancer patients.\n\nStudy design: Prospective, observational cohort study Study population: All AYAs diagnosed (18-39 years at primary diagnosis) with cancer (any type) within the first 3 months after diagnosis (eligibility window of 1 month to ensure all eligible AYA cancer patients can be included) in one of the participating centres (or treated in one of these centres) in The Netherlands.\n\nMain study parameters\u002Fendpoints: The main outcomes are medical (e.g. second tumour; survival; fertility) and psychosocial (e.g. distress) health outcomes. Other study parameters (covariates\u002Fmoderators\u002Fmediators) are characteristics of the individual (e.g. age, sex, cultural background, partner status, educational level, occupation, tumour type, disease stage, body composition, comorbid conditions, coping style), characteristics of the environment (e.g. cancer treatment, lifestyle), and genetic and biological factors (e.g. family history of cancer, stress and inflammation markers (e.g. cortisol, IL-6), microbiome).\n\nNature and extent of the burden and risks associated with participation, benefit and group relatedness: On an individual level, patients who participate are asked to complete questionnaires on an annual basis for at least 10 years. All sample collections will take place at three time points: 0-3 months after diagnosis (baseline), 2 and 5 years; except blood for DNA analyses which will only take place at baseline. The collection of blood, hair and faeces at three occasions is minimally invasive and the risks of blood draws, hair and fecal sampling are negligible. All safety measures and procedures will be performed according to local guidelines. Patients will not experience direct benefit from participation in the COMPRAYA study.\n\nBy participating, patients will contribute to a better insight in the prevalence of impaired medical and psychosocial (age-specific) health outcomes in AYA and evidence on factors associated with these health outcomes. This will lead to better and more personalized cancer care and supportive care tools for future AYA cancer patients.",[432,433,29,434,119,435,145],"Second Cancer","Survivorship","Distress, Emotional","Genetic Disease","2022-02-11",{"date":438,"type":35},"2022-03-02",{"date":440,"type":35},"2021-06-18",{"date":442,"type":21},"2035-06",{"name":444,"class":42},"The Netherlands Cancer Institute"]